Risankizumab

1 Drug classified under this active ingredient

Immunosuppressant. Risankizumab 150 mg.
Pre-fil. syr/pen with sol. for SC inj. with 150 mg
For mod. to sev. plaque psor. in adlts. who are candidates for syst. ther. Alone or in comb. with methotrexate (MTX) for act. psoriatic arthr. in adlts who had an inadeq. resp.or who have intol. to one or more dis.-modifying antirheum. drugs (DMARDs). Recom. dose 150 mg admin. at week 0, week 4, and every 12 weeks thereafter one 150 mg pre-filled pen or pre-filled syr. inject).
C/I: Hypersens. Clinic. import. act. infect. (e.g. act.TB)